Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology firm, will ring the Nasdaq opening bell at MarketSite in Times Square, New York on Wednesday, August 28, 2024.
“Today, we celebrate the launch of Shield, our FDA-approved blood-based test for colorectal cancer screening, by ringing the Nasdaq opening bell. This milestone marks a significant step in our mission to combat cancer through data,” said AmirAli Talasaz, co-CEO of Guardant Health. “Shield provides a more comfortable way to keep up with colorectal cancer screening and detect the disease early, when treatment is most effective. This achievement is a landmark moment for Guardant, the field of liquid biopsy, cancer screening, and, most importantly, for patients. I want to thank our team for their dedication over the past decade.”
The Nasdaq Opening Bell ceremony will be broadcast live starting at 8:30 a.m. Eastern Time on August 28, 2024. Watch it at: Nasdaq Opening Bell.
Following the bell ringing, management will participate in a Behind the Bell interview, available at Nasdaq Behind the Bell.
Guardant Health’s team will be in New York City from August 28 – 29, 2024, for media interviews and investor meetings. For inquiries, please contact [email protected] or [email protected].
About Guardant Health
Guardant Health, founded in 2012, is a leading precision oncology company dedicated to improving cancer care and extending lives. The company leverages advanced blood and tissue tests, real-world data, and AI analytics to provide critical insights into cancer progression. Guardant’s solutions support all stages of care, from early detection and monitoring to treatment selection for advanced cancer.
